IGC Pharma (IGC) Accounts Payables (2011 - 2026)
IGC Pharma (IGC) posted quarterly Accounts Payables of $1.3 million for Q1 2026, up 42.13% year-over-year from $883000.0 in Q1 2025, and up 23.77% quarter-over-quarter from $1.0 million in Q4 2025.
IGC Pharma (IGC) Accounts Payables (2011 - 2026) Analysis & Trends
IGC Pharma (IGC) has reported Accounts Payables for 16 consecutive years, with $1.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 42.13% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $1.3 million (up 42.13% YoY), while the FY2026 annual figure was $1.3 million, up 42.13% from the prior year.
- Accounts Payables improved to $1.3 million in Q1 2026 per IGC's latest filing, from $1.0 million in the prior quarter.
- Across five years, Accounts Payables topped out at $1.6 million in Q3 2023 and bottomed at $456000.0 in Q2 2022.
- Historically, Accounts Payables has averaged $903647.1 across 5 years, with a median of $835000.0 in 2024.
- Annual changes were most pronounced in 2022 — Accounts Payables tumbled 70.43% — and 2023, when it surged 219.96%.
- IGC Pharma's Accounts Payables stood at $466000.0 in 2022, then jumped by 39.06% to $648000.0 in 2023, then gained by 28.86% to $835000.0 in 2024, then climbed by 21.44% to $1.0 million in 2025, then grew by 23.77% to $1.3 million in 2026.
- Business Quant data shows IGC's Accounts Payables at $1.3 million in Q1 2026, $1.0 million in Q4 2025, and $628000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.65 Bn | 131.79 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.08 Bn | 78.09 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 63.25 Bn | 58.11 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.26 Bn | 27.95 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.96 Bn | 10.57 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.35 Bn | - | 35.57 Mn |
| 10 | IGC Pharma | 28.21 Mn | 27.95 Mn | - | 1.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.26 Mn |
| Dec 31, 2025 | 1.01 Mn |
| Sep 30, 2025 | 628,000.00 |
| Jun 30, 2025 | 933,000.00 |
| Mar 31, 2025 | 883,000.00 |
| Dec 31, 2024 | 835,000.00 |
| Sep 30, 2024 | 768,000.00 |
| Jun 30, 2024 | 771,000.00 |
| Mar 31, 2024 | 773,000.00 |
| Dec 31, 2023 | 648,000.00 |
| Sep 30, 2023 | 1.56 Mn |
| Jun 30, 2023 | 1.46 Mn |
| Mar 31, 2023 | 530,000.00 |
| Dec 31, 2022 | 466,000.00 |
| Sep 30, 2022 | 926,000.00 |
| Jun 30, 2022 | 456,000.00 |
| Mar 31, 2022 | 1.46 Mn |
| Dec 31, 2021 | 357,000.00 |
| Sep 30, 2021 | 1.59 Mn |
| Jun 30, 2021 | 1.54 Mn |